Pieris Pharmaceuticals, Inc. PI6.F Stock
Pieris Pharmaceuticals, Inc. Price Chart
Pieris Pharmaceuticals, Inc. PI6.F Financial and Trading Overview
| Pieris Pharmaceuticals, Inc. stock price | 0.15 EUR |
| Previous Close | 0.82 EUR |
| Open | 0.8 EUR |
| Bid | 0.82 EUR x 500000 |
| Ask | 0.85 EUR x 500000 |
| Day's Range | 0.8 - 0.8 EUR |
| 52 Week Range | 0.64 - 2.08 EUR |
| Volume | 1K EUR |
| Avg. Volume | 663 EUR |
| Market Cap | 65.37M EUR |
| Beta (5Y Monthly) | 1.078873 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | 0 EUR |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 8.5 EUR |
PI6.F Valuation Measures
| Enterprise Value | 35.08M EUR |
| Trailing P/E | N/A |
| Forward P/E | -1.0088607 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 3.8794792 |
| Price/Book (mrq) | 3.8502414 |
| Enterprise Value/Revenue | 2.082 |
| Enterprise Value/EBITDA | -0.716 |
Trading Information
Pieris Pharmaceuticals, Inc. Stock Price History
| Beta (5Y Monthly) | 1.078873 |
| 52-Week Change | -42.80% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 2.08 EUR |
| 52 Week Low | 0.64 EUR |
| 50-Day Moving Average | 0.8 EUR |
| 200-Day Moving Average | 1.09 EUR |
PI6.F Share Statistics
| Avg. Volume (3 month) | 663 EUR |
| Avg. Daily Volume (10-Days) | 877 EUR |
| Shares Outstanding | 82.02M |
| Float | 38.57M |
| Short Ratio | N/A |
| % Held by Insiders | 9.84% |
| % Held by Institutions | 59.36% |
| Shares Short | N/A |
| Short % of Float | N/A |
| Short % of Shares Outstanding | N/A |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | -245.45% |
| Operating Margin (ttm) | -305.80% |
| Gross Margin | -210.62% |
| EBITDA Margin | -290.78% |
Management Effectiveness
| Return on Assets (ttm) | -29.36% |
| Return on Equity (ttm) | -120.040% |
Income Statement
| Revenue (ttm) | 16.85M EUR |
| Revenue Per Share (ttm) | 0.23 EUR |
| Quarterly Revenue Growth (yoy) | -82.39% |
| Gross Profit (ttm) | -27080000 EUR |
| EBITDA | -48998000 EUR |
| Net Income Avi to Common (ttm) | -41359000 EUR |
| Diluted EPS (ttm) | -0.54 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 48.38M EUR |
| Total Cash Per Share (mrq) | 0.59 EUR |
| Total Debt (mrq) | 13.09M EUR |
| Total Debt/Equity (mrq) | 84.67 EUR |
| Current Ratio (mrq) | 1.411 |
| Book Value Per Share (mrq) | 0.207 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -48285000 EUR |
| Levered Free Cash Flow (ttm) | -23408000 EUR |
Profile of Pieris Pharmaceuticals, Inc.
| Country | Germany |
| State | MA |
| City | Boston |
| Address | 225 Franklin Street |
| ZIP | 02110 |
| Phone | 857 246 8998 |
| Website | https://www.pieris.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 127 |
Pieris Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops anticalin-based drugs. The company develops anticalin proteins that are low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins found in human blood plasma and other bodily fluids. Its lead respiratory Anticalin based drug candidate, elarekibep used for the treatment of asthma; and PRS-220, an oral inhaled Anticalin protein targeting connective tissue growth factor for the treatment of idiopathic pulmonary fibrosis. The company also develops PRS-344/S09501 2that consists of a PD-L1-targeting antibody and 4-1BB-targeting Anticalin proteins. It has a license and collaboration agreement with Les Laboratoires Servier and Institut de Recherches Internationales Servier, AstraZeneca AB, and Seagen Inc.; and license agreements with Technical University of Munich and Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd. Pieris Pharmaceuticals, Inc. was incorporated in 2000 and is headquartered in Boston, Massachusetts.
Q&A For Pieris Pharmaceuticals, Inc. Stock
What is a current PI6.F stock price?
Pieris Pharmaceuticals, Inc. PI6.F stock price today per share is 0.15 EUR.
How to purchase Pieris Pharmaceuticals, Inc. stock?
You can buy PI6.F shares on the Frankfurt exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Pieris Pharmaceuticals, Inc.?
The stock symbol or ticker of Pieris Pharmaceuticals, Inc. is PI6.F.
Which industry does the Pieris Pharmaceuticals, Inc. company belong to?
The Pieris Pharmaceuticals, Inc. industry is Biotechnology.
How many shares does Pieris Pharmaceuticals, Inc. have in circulation?
The max supply of Pieris Pharmaceuticals, Inc. shares is 103.8M.
What is Pieris Pharmaceuticals, Inc. Price to Earnings Ratio (PE Ratio)?
Pieris Pharmaceuticals, Inc. PE Ratio is 0.00000000 now.
What was Pieris Pharmaceuticals, Inc. earnings per share over the trailing 12 months (TTM)?
Pieris Pharmaceuticals, Inc. EPS is 0 EUR over the trailing 12 months.
Which sector does the Pieris Pharmaceuticals, Inc. company belong to?
The Pieris Pharmaceuticals, Inc. sector is Healthcare.